Vol 7, Supplement 6 (July 30, 2018): Translational Cancer Research (Prostate Cancer: Current Understanding and Future Directions)

Review Article

Hypofractionation in prostate cancer radiotherapy
David J. Brenner, Eric J. Hall
Translational Cancer Research  
2018;
7
(Suppl 6)
:S632-S639
.
Genetic signatures on prostate biopsy: clinical implications
Justin T. Matulay, Sven Wenske
Translational Cancer Research  
2018;
7
(Suppl 6)
:S640-S650
.
Prostate cancer: unmet clinical needs and RAD9 as a candidate biomarker for patient management
Howard B. Lieberman, Alex J. Rai, Richard A. Friedman, Kevin M. Hopkins, Constantinos G. Broustas
Translational Cancer Research  
2018;
7
(Suppl 6)
:S651-S661
.
Neoadjuvant therapies for surgical management of high risk, localized prostate cancer
Nina Mikkilineni, Elias S. Hyams
Translational Cancer Research  
2018;
7
(Suppl 6)
:S662-S675
.
Prostate-specific membrane antigen in prostate cancer imaging and treatment
Emerson Lim
Translational Cancer Research  
2018;
7
(Suppl 6)
:S676-S689
.
2nd generation anti-androgens and radiotherapy for localized prostate cancer
Tomer Charas, Sean McBride
Translational Cancer Research  
2018;
7
(Suppl 6)
:S690-S694
.
Androgen deprivation therapy and radiation therapy for prostate cancer: the mechanism underlying therapeutic synergy
Catherine S. Spina
Translational Cancer Research  
2018;
7
(Suppl 6)
:S695-S703
.

Editorial

Genetic signatures on radical prostatectomy specimens: clinical implications
Christopher B. Anderson, G. Joel DeCastro
Translational Cancer Research  
2018;
7
(Suppl 6)
:S704-S710
.

Disclosure:

The supplement “Prostate Cancer: Current Understanding and Future Directions” was commissioned by the editorial office, Translational Cancer Research without any sponsorship or funding. Israel Deutsch, Charles G Drake and James McKiernan served as the unpaid Guest Editors for the supplement.